Dr. Meriem Bouslouk-Marx

Dr. Meriem Bouslouk-Marx is the founder of MBM Future Health. She has comprehensive experience in the assessment of new pharmaceuticals and the procedures at Germany’s top health policy body, the Federal Joint Committee (G-BA). When Germany introduced AMNOG, the legislation on the benefit assessment of new innovative medicines, in 2011, she joined the initial small team at the G-BA in charge of implementing the procedure. In this position, she prepared binding national decisions.
Her main responsibilities included conducting consultations with industry and regulatory authorities on clinical trial design and endpoints, assessing the submitted evidence and drafting G-BA resolutions under AMNOG. Equipped with her knowledge of neglected diseases, she conceptualised and co-ordinated the specific German policy procedure for the assessment of new orphan drugs. Her daily work included interaction with various stakeholders, reaching from healthcare payers, healthcare providers, patients and their affiliations to pharmaceutical manufacturers and associations.
Special time-limited permission to be on leave from the Pharmaceuticals Department was granted in 2016 to set up the G-BA’s new Innovation Committee after the introduction of Germany’s Innovation Fund. Furthermore, Meriem was entrusted to promote the G-BA’s work at international level, which became a real passion: she gave lectures and speeches – within and outside of the G-BA – and strengthened partnerships with other European and international organisations.